Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. 3 Eylül 2026 tarihinde ne bildirdi

Şirketin kendi 8-K belgesinden.

Kazanç çağrıları

Latigo Biotherapeutics, Inc. için kazanç çağrısı dökümü mevcut değil.

Yönetim ne dedi

“This has been a significant period for Latigo as we completed our upsized initial public offering, published positive onzotrigine abdominoplasty results in moderate-to-severe acute pain in The New England Journal of Medicine, and continued to advance our pipeline of innovative pain programs,”

Açıklamadan birebir alıntılanmıştır ve yalnızca belge sözü adı geçen bir kişiye atfettiğinde gösterilir.

Fiyat nasıl tepki verdi

Açıklamalar kapanıştan sonra ya da açılıştan önce gelir, dolayısıyla hareket bir sonraki seansa aittir.

Latigo Biotherapeutics, Inc. ne yapar

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines. Latigo’s drug candidates are designed to rapidly and effectively stop the transmission of pain without the risk of addiction. The Company’s lead product candidate, onzotrigine (previously referred to as LTG-001) is an oral Na v 1.8 ion channel inhibitor intended to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is an oral Na v 1.8 inhibitor being developed for chronic musculoskeletal pain. Additionally, Latigo is advancing research of additional Na v 1.8 inhibitors that can address alternative formulation and delivery approaches as well as other ion channel targets for the treatment of pain. Learn more at latigobio.com or follow us on LinkedIn and X .

Şirketin kendi tanımı, açıklamanın sonunda göründüğü hâliyle.